Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05631678

Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

Locally Advanced or Metastatic NSCLC Clinical Trial

Official title:
An Open-lable, Two- Period, Single-sequence, Self-controlled Study to Evaluate the Effect of Oral Rifampicin or Itraconazole on the Pharmacokinetics of ASK120067 Tablets

Clinical Trial Summary

To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of ASK120067 and its metabolite CCB4580030 in healthy subjects. To evaluate the safety of ASK120067 tablets or combination with rifampicin capsules or itraconazole capsules in healthy subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Locally Advanced or Metastatic NSCLC
Clinical Trial Details
NCT number NCT05631678
Study type Interventional
Source Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Contact
Status Completed
Phase Phase 1
Start date June 6, 2022
Completion date August 3, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT03037086 - Asia PDL1 Study Among NSCLC Patients N/A
Recruiting NCT05662670 - A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03274479 - PBF-1129 in Patients With NSCLC Phase 1
Recruiting NCT03502850 - Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT05990127 - A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer Phase 3
Active, not recruiting NCT03969823 - Whole Genomic Landscape of Advanced EGFR-mutant NSCLC N/A
Completed NCT04207775 - Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
Not yet recruiting NCT06461156 - A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) Phase 1
Active, not recruiting NCT04143607 - ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC Phase 3
Completed NCT03414814 - Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation Phase 2
Completed NCT04360915 - Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects Phase 1